This technology is a pharmacological method to prevent and treat myopia using fingolimod and its derivatives.
Although myopia is an increasingly common eye disorder, there is currently no therapeutic that can prevent and treat myopia symptoms effectively. Current treatments for myopia include optical correction with spectacles and contact lenses, or drugs like atropine, which tend to have low efficacy or significant adverse effects. These treatments are focused on slowing down the progression of the disease without specifically targeting the mechanisms underlying myopia.
Through a pharmacological pipeline combining systems genetics and computation, fingolimod, a sphingosine-1-phosphate receptor modulator, was found to have high antimyopic potential. This compound uniquely targets the mechanisms causing myopia in addition to the associated symptoms, and is already FDA-approved for the treatment of multiple sclerosis. The drug can be administered orally, topically, or through injections, making it a versatile therapeutic for treatment and prevention of myopia in children and adults.
This technology has been validated with mouse models.
IR CU20382
Licensing Contact: Kristin Neuman
